Revenue Showdown: Biogen Inc. vs Bausch Health Companies Inc.

Biogen's revenue growth outpaces Bausch Health over a decade.

__timestamp	Bausch Health Companies Inc.	Biogen Inc.
Wednesday, January 1, 2014	8263500000	9703324000
Thursday, January 1, 2015	10498800000	10763800000
Friday, January 1, 2016	9674000000	11448800000
Sunday, January 1, 2017	8724000000	12273900000
Monday, January 1, 2018	8380000000	13452900000
Tuesday, January 1, 2019	8601000000	14377900000
Wednesday, January 1, 2020	8027000000	13444600000
Friday, January 1, 2021	8434000000	10981700000
Saturday, January 1, 2022	8124000000	10173400000
Sunday, January 1, 2023	8757000000	9835600000
Monday, January 1, 2024		9675900000

Unleashing insights

Revenue Showdown: Biogen Inc. vs Bausch Health Companies Inc.

In the ever-evolving landscape of the pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Biogen Inc. and Bausch Health Companies Inc. have been at the forefront of this competitive arena. From 2014 to 2023, Biogen consistently outperformed Bausch Health, with revenues peaking in 2019 at approximately 14.4 billion USD, a 48% increase from 2014. In contrast, Bausch Health's revenue saw a more modest peak in 2015, with a 27% increase from 2014, before stabilizing around 8.7 billion USD in 2023. This data highlights Biogen's robust growth trajectory, driven by its innovative therapies and strategic market positioning. As the industry continues to evolve, these companies' financial performances will be crucial in shaping their future roles in the global market.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025